Moderately Ill COVID-19 Patients Treated with Therapeutic-Dose Anticoagulation Have Better Chances of Survival

Moderately ill patients hospitalized with COVID-19 have better chances of survival if treated with therapeutic-dose anticoagulation, according to a new study.

The international study involving 121 sites, including UT Southwestern Medical Center (Dallas, TX, USA), found that moderately ill COVID-19 patients treated with therapeutic-dose anticoagulation with unfractionated or low molecular-weight heparin were 27% less likely to need cardiovascular respiratory organ support such as intubation. Moderately ill patients had a 4% increased chance of survival until discharge without requiring organ support with anticoagulants, according to the study involving 2,200 patients.


“The 4% increase in survival to discharge without needing organ support represents a very meaningful clinical improvement in these patients,” said Dr. Ambarish Pandey, M.D., Assistant Professor of Internal Medicine at UT Southwestern, who served as site investigator and co-author of the study. “If we treat 1,000 patients who are hospitalized with COVID-19 with moderate illness, an additional 40 patients would have meaningful improvement in clinical status.”

Related Links:
UT Southwestern Medical Center